| - Quarter Highlighted by Record Net Product Sales, European Launch of Cinryze® (C1 esterase inhibitor [human]) and European Approval of Buccolam® (midazolam, oromucosal solution) - EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2011. In the third quarter of 2011, we: Achieved a record $143 million in net product sales, representing 21 percent growth over the third quarter of ...continued ILNS VPHM Drugs neurosciences Healthcare |
Thursday, October 27, 2011
ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment